Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randi Grøn

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|October 2, 2015
Misspecified poisson regression models for large-scale registry data: inference for 'large n and small p'Randi Grøn, Thomas A Gerds, Per K Andersen
Biometrical Journal. Biometrische Zeitschrift|September 17, 2013
Nonparametric estimation in an "illness-death" model when all transition times are interval censoredHalina Frydman, Thomas Gerds, Randi Grøn, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 25, 2013
Authors' replyLars Vedel Kessing, Randi Grøn, Per Kragh Andersen
BMC Cancer|August 24, 2017
Active smoking and risk of breast cancer in a Danish nurse cohort studyZorana Jovanovic Andersen, Jeanette Therming Jørgensen, Randi Grøn, et al.
Psychopharmacology|March 5, 2013
The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational ageHans Mørch Jensen, Randi Grøn, Ojvind Lidegaard, et al.
The British Journal of Psychiatry : the Journal of Mental Science|February 23, 2013
Maternal depression, antidepressant use in pregnancy and Apgar scores in infantsHans Mørch Jensen, Randi Grøn, Øjvind Lidegaard, et al.
Diabetes Care|February 28, 2018
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical TrialLiana K Billings, Ankur Doshi, Didier Gouet, et al.
Journal of Diabetes Science and Technology|February 29, 2020
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized TrialLiana K Billings, Bue F Ross Agner, Yuksel Altuntas, et al.
Diabetes, Obesity & Metabolism|August 7, 2019
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapyEden Miller, Ankur Doshi, Randi Grøn, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trialVanita R Aroda, Guillermo González-Galvez, Randi Grøn, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|October 2, 2015
Misspecified poisson regression models for large-scale registry data: inference for 'large n and small p'Randi Grøn, Thomas A Gerds, Per K Andersen
Biometrical Journal. Biometrische Zeitschrift|September 17, 2013
Nonparametric estimation in an "illness-death" model when all transition times are interval censoredHalina Frydman, Thomas Gerds, Randi Grøn, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 25, 2013
Authors' replyLars Vedel Kessing, Randi Grøn, Per Kragh Andersen
BMC Cancer|August 24, 2017
Active smoking and risk of breast cancer in a Danish nurse cohort studyZorana Jovanovic Andersen, Jeanette Therming Jørgensen, Randi Grøn, et al.
Psychopharmacology|March 5, 2013
The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational ageHans Mørch Jensen, Randi Grøn, Ojvind Lidegaard, et al.
The British Journal of Psychiatry : the Journal of Mental Science|February 23, 2013
Maternal depression, antidepressant use in pregnancy and Apgar scores in infantsHans Mørch Jensen, Randi Grøn, Øjvind Lidegaard, et al.
Diabetes Care|February 28, 2018
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical TrialLiana K Billings, Ankur Doshi, Didier Gouet, et al.
Journal of Diabetes Science and Technology|February 29, 2020
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized TrialLiana K Billings, Bue F Ross Agner, Yuksel Altuntas, et al.
Diabetes, Obesity & Metabolism|August 7, 2019
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapyEden Miller, Ankur Doshi, Randi Grøn, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trialVanita R Aroda, Guillermo González-Galvez, Randi Grøn, et al.
Pageof 2